Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 103,389

Document Document Title
WO/2014/146493A1
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.  
WO/2014/150981A1
The present invention provides compounds having a structure according to Formula I. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and com...  
WO/2014/153226A1
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using...  
WO/2014/152444A1
Proivded herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDACl, HDAC2, and HDAC3).  
WO/2014/148455A1
Provided is a novel terpenoid derivative which exhibits anti-inflammatory action and cytoprotective action by activating Keap1/Nrf2/ARE signal transduction pathways. Terpenoid derivative A is represented by formula (1).  
WO/2014/151628A1
Methods are provided for treating Autism Spectrum Disorder (ASD) using helminthic parasite preparations.  
WO/2014/151742A1
Disclosed herein are stable pharmaceutical dosage forms containing carbidopa, levodopa, and entacapone. The dosage forms are prepared by mixing carbidopa, levodopa, and entacapone and forming granules. In some embodiments the granules al...  
WO/2014/151747A1
Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.  
WO/2014/152725A1
Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). Formula (1)  
WO/2014/151529A1
The present invention provides compounds, compositions, kits, and methods which are effective for mitigating, treating, or ameliorating a DNA repair-deficiency disorder or a symptom of a DNA repair-deficiency disorder. The compounds, com...  
WO/2014/151697A1
Provided herein are compositions, including intranasal compositions, which include geranylgeranyl acetone (GGA) and/or derivatives thereof and methods for treating a neural disease, disorder or condition with the same. Also provided here...  
WO/2014/151719A1
Provided herein are sublingual formulations of geranylgeranylacetone, geranylgeranylacetone derivatives, and drug conjugates of each thereof, and methods of using them. Also provided are methods for treating osteopenia with geranylgerany...  
WO/2014/146490A1
Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.  
WO/2014/151258A1
The present invention is directed to substituted pyridine derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives in the treatment of disorders mediated by c-fms kinase. The present invention ...  
WO/2014/150687A1
The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant and/or lactating woman for improving one or more characteristics in offspring, for example cognition and/or bone health. The carbohyd...  
WO/2014/151393A3
The present disclosure provides substituted pyridyl-, pyrimidinyl-, pyrazinyl-, pyridazinyl-, and triazinyl-based carboxamides of Formula I-A: R10 Z-HET-E I-A and the pharmaceutically acceptable salts and solvates thereof, wherein Z, HET...  
WO/2014/152621A1
The present invention is directed to a compound of Formula (I): wherein: The present invention is directed to a compound of Formula (I): wherein: • n is an integer from 0-1; • X is CH2 when n is 0, or X is CH2 or oxygen when n is 1; ...  
WO/2014/147353A1
The invention relates to the use of 4-{3-[cis-hexahydrocyclopenta[C]pyrrole-2(1H)-yl]propoxy}ben zamide of formula (I): or of the acid or base addition salts thereof, which is pharmaceutically acceptable for treating neuropathic pain as ...  
WO/2014/146553A1
The present invention belongs to the field of pharmaceutical chemistry, and, in particular, disclosed therein are a flavonoid derivative and use thereof. Disclosed is a flavonoid derivative having the structure of general formula (I) or ...  
WO/2014/153172A1
Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using ...  
WO/2014/152144A1
Compounds of formula (I) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect.  
WO/2014/151387A1
Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the composition...  
WO/2014/153529A1
The invention provides modulators of the nociceptin receptor (NOP), including both agonists and antagonists. A compound of the invention can be a selective modulator of NOP with respect to the μ- and κ- opioid receptors (MOP and KOP), ...  
WO/2014/152589A1
The present invention is directed to a compound of Formula (I) or (la) The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) or (la) and methods comprising administering of compounds of Formula (I)...  
WO/2014/153226A9
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using...  
WO/2014/151338A1
The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis.  
WO/2014/144512A1
A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are meth...  
WO/2014/139443A1
Provided are a low immunogenicity human cell and a preparation method therefor. The cell is a modified human cell. Compared with a corresponding wild-type cell, the human leukocyte antigen (HLA) protein or polypeptide of surface of the c...  
WO/2014/144231A1
The invention relates to methods for treating stress sensitive condition. For instance a subject having or at risk of having a stress-sensitive condition may be treated with a growth hormone (GH) antagonist in an effective amount to trea...  
WO/2014/140086A1
The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: (I). In formula I the variables X1 is CH or N, X2 is O or S and where R1, R2, R3, R4 an...  
WO/2014/146082A1
Methods, apparatus, compositions and kits for inhibiting a disorder in a human patient, including non-cerebral neurovascular disorder or muscular headache pain, or loss of motor or sensory function, sympathetic tone or range or fluidity ...  
WO/2014/140802A3
Novel three-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided. Three-component formulations of the invention comprise biologically active forms of at least one neurosteroid,...  
WO/2014/138791A1
The present invention relates to transgenic animal models. Specifically, the present invention relates to transgenic animal models for applications associated with TSPO-related normal physiology, diseases and disorders. The present inven...  
WO/2014/139882A1
The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 ...  
WO/2014/145118A1
Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative di...  
WO/2014/144100A3
Compounds of Formulae (I') and (I) are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders tha...  
WO/2014/140186A1
The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.  
WO/2014/142519A1
The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising t...  
WO/2014/142548A1
The present invention relates to a composition for preventing or treating a nerve gas-induced disease comprising a phenyl carbamate compound and a method for preventing or treating a nerve gas-induced disease therewith. The present inven...  
WO/2014/139150A1
The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present...  
WO/2014/143666A1
Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I).  
WO/2014/143799A3
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.  
WO/2014/142520A1
The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising t...  
WO/2014/139227A1
A lump sugar contains monosialotetera-hexosyl ganglioside of 0.01-3% by weight, brain protein of 1-98% by weight, and chicory polysaccharide of 1-98% by weight.  
WO/2014/142477A1
The present invention provides a pharmaceutical composition for preventing and/or treating a pediatric epilepsy or epilepsy-related syndrome comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbam...  
WO/2014/138814A1
The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can al...  
WO/2014/141219A1
The present invention relates to umbilical cord blood derived mesenchymal stem cells (UCBMSCs) for use in treating a neural disorder in a subject such as a placental mammal, wherein said cells are to be administered by (i) intravenous ad...  
WO/2014/141261A1
The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, o...  
WO/2014/143799A9
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.  
WO/2014/140313A1
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, f...  

Matches 351 - 400 out of 103,389